Otsuka’s VOYXACT Shows First IgAN Therapy to Stabilize Kidney Function Decline to Normal Physiologic Levels on August 04, 2026 APRIL inhibitor decline Epidermal Growth Factor Receptor IgA IGA Glomerulonephritis KDIGO Otsuka Phase 3 physiologic rate Renal function Stabilization VISIONARY Voyxact +
AC Immune Reports Promising Phase 2 Interim Data for Parkinson's Immunotherapy ACI-7104.056 on December 12, 2025 ACI-7104.056 Actinium alpha-Synuclein Biological Markers Immune Parkinson 's disease Phase 2 trial Stabilization +